multiple myeloma
Conditions
Interventions
None listed
Sponsors
Gunma Hematological Disease Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) symptomatic myeloma according to the criteria ofIMWG. (2)Relapsed and refractory myeloma after at least 1 treatment regimen. (3)Patients who know they had multiple myeloma. (4)Patients who are planned to be treated with thalidomide. (5)Patients who had measurable M-protein.(IgG >= 1.0 g/dl, IgA, IgD >=0.5g/dl) or urin M-protein(>=0.2 g/day). (6)>=20 years-old (7)Patients with ECOG performance status:0-2 (Patients with PS 3 restricted by bone lesions are allowed to participate) (8)Patients who are mached the below; 1)neutrophil count>=1,000/mm3 2)platelet count >=5x104/mm3 3)AST <=X2.5 of upper limit 4)ALT <=X2.5 of upper limit 5)Total bilirubin <=X1.5 of upper limit 6)SaO2 >= 90%(room air) (9)No deep vein thrombosis or pulmonary embolism. (10)Patients who have given written informed consent.
Exclusion criteria
Exclusion criteria: (1) patients with uncontrollable infection. (2)patients with psychological diseases. (3)female who can have children. (4)patients who the doctor think unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of adverse events and response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year progression free survival and 2-year overall survival | — |
Countries
Japan
Contacts
Public ContactGunma Hematology Study Group
Gunma Graduate School of Health Scineces Gunma Graduate School of Health Scineces
Outcome results
None listed